Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 643Other hematologic neoplasm 459Breast 338Plasma cell 184Myeloid 132Sarcoma 110CNS 87Dermatologic 85Classical hematology 54Gynecologic 50Gastrointestinal 46Genitourinary 43Thoracic 35Other solid neoplasm 24Head & Neck 13Tumor-Agnostic 9Other neoplasm 4Other 2Endocrine 2NET 1

Conditions

Neuroendocrine Tumors 1

Interventions

Everolimus 19lutetium Lu 177 dotatate 8Octreotide 8lanreotide 7pasireotide 6Temozolomide 6Sunitinib 6pembrolizumab 5gallium Ga 68 dotatate 5Positron Emission Tomography Computed Tomography 5surufatinib 4Sorafenib 4Data Collection 4Carboplatin 43-Iodobenzylguanidine 4Positron-Emission Tomography 3Nivolumab 3Magnetic Resonance Spectroscopy 3Etoposide 3Capecitabine 390Y-octreotide, DOTA-Tyr(3)- 3pentetreotide 2pazopanib 2lenvatinib 2fosbretabulin 2fluorodopa F 18 2cabozantinib 2avelumab 2arginyllysine 2Single Photon Emission Computed Tomography Computed Tomography 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Cyclophosphamide × NET × Clear all
NCT00605566 2019-02-19

Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors

University Health Network, Toronto

Phase 2 Completed
22 enrolled 10 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡